Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Trial details
- Registry ID
- NCT04224272
- Phase
- Phase 2
The FDA approved Palbociclib (IBRANCE) on 3 Feb 2015.
Drug identity checked against registry records
Also recorded as IBRANCE; PD-0332991
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantNCT04224272 | Jazz Pharmaceuticals | Phase 2 | Completed | 2023-04-28Actual |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 | CELC | Phase 3 | Active not recruiting | 2026-06-30Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2015-02-03Day | Palbociclib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA207103", "applicant_as_listed_by_fda": "PFIZER", "brand_names": ["IBRANCE"], "active_ingredients": ["PALBOCICLIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20150203", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |